2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - Great Hall AD
Access, Representation, Population Health, Treatment Considerations, Biological Therapies, Transfusion, Non-Biological Therapies, Palliative Care, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, MDS, Clinical Research, Real-World Evidence, Study Population, Human, Adult, Pediatric
PAPER

323 Transfusion is a disproportionate barrier to hospice utilization in patients with myeloid malignancies or acute lymphoblastic leukemia

Chiara Lucia Perni, N/A, Kathryn (Katie) D. Russell, ARNP2, Catherine Fedorenko3, Veena Shankaran, MD4, Winona E Wright5, Camille Wu6, Mary-Elizabeth Percival, MD7, Jacob S Appelbaum, Md, PhD8
1 University of Washington, Seattle, Washington, United States
2 University of Washington, Seattle, Washington, United States
3 Fred Hutchinson Cancer Center, Seattle, Washington, United States
4 Fred Hutchinson Cancer Center, Seattle, Washington, United States, Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
5 Fred Hutchinson Cancer Center, Seattle, Washington, United States
6 Fred Hutchinson Cancer Center, Seattle, Washington, United States
7 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
8 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States

Background: For patients with cancer who have <6 months to live, hospice care improves quality of life (QOL) and reduces psychological distress. However, hospice remains inaccessible to many with acute lymphoblastic leukemia (ALL) or myeloid neoplasms (MN), such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The impacts of policy structures on barriers to hospice access remain poorly described. One major barrier to hospice for patients with MN is the frequent need for transfusions. The cost of a single blood transfusion typically exceeds hospice’s global bundled per diem rate by 8-10x, preventing many hospice providers from covering this service. Surveys suggest some patients are forced to choose between hospice enrollment or transfusion access.

We used the Hutchinson Institute for Cancer Outcomes Research (HICOR) data repository, which links cancer registry, health care claims, and financial records for >600,000 individuals in Washington State, to comprehensively assess impacts of transfusion dependence on hospice care in patients with MN or ALL to identify potentially modifiable system-level and provider-level factors contributing to disparate hospice utilization.

Methods: Patients aged >18 yrs who died after a diagnosis of ALL, AML, or MDS were identified in the HICOR data repository (2011-2024). Hospice enrollment and transfusions of blood or platelets in the 3 months prior to death was abstracted from claims data. Demographic details included age, gender, race, private vs public insurance coverage, and geographic location including area deprivation index (ADI). The primary outcomes were hospice enrollment and duration of hospice care. Correlation of demographic factors including socioeconomic and racial disparities with hospice access was assessed using multivariate logistic models or generalized linear models.

Results: From the HICOR Data Repository (n=626,880), we identified 2,377 patients (pts) meeting the inclusion criteria. In this group, 45.9% met criteria for hospice enrollment, though hospice tenure >30 days was only observed in 10% of pts. Mean age was 71.4 years, 57.1% were male, and race was self-reported as White (87%), Black (2.5%), Asian (3.4%), Hispanic (4.4%), and other (2.9%). Cancer types were AML (70.8%), MDS (20.5%), or ALL (8.7%). The most common payor was Medicare (61.5%), others were commercial insurance (9.6%), Medicaid (11.3%), or multiple carriers (17.7%). 70.2% resided in metropolitan areas while 16.9% were in micropolitan or rural areas.

Among the entire cohort, 72.9% received ≥1 transfusion in the 3 months prior to death (mean ± SD transfusions=11.6±21.53). Transfused pts were less likely to have enrolled in hospice for >3 days. Linear regression showed an inverse correlation between transfusion requirement and duration of hospice enrollment (R2=0.06, p<0.001).

Pts with AML and those with multi-payor coverage received more transfusions 30 days prior to death or hospice enrollment, suggesting this group may suffer unique impacts. Multivariate logistic regression found older (OR=1.04, p=< 0.001) or female (OR=1.374, p=0.0006) pts were more likely to enroll in hospice. Pts with AML (OR=0.595 vs ALL, p=0.0027) or MDS (OR=0.0531, p=0.0015 vs ALL), self-reporting race as Black (OR=0.0452, p=0.03) or Asian (OR=0.527, p=0.0275), those not in metropolitan areas (OR=0.66, p=0.015), or who resided in disadvantaged neighborhoods (vs ADI 1-4, OR=0.753, p=0.01) were less likely to enroll. Associations showing decreased enrollment for pts with commercial insurance, with AML (vs ALL) and areas with ADI > 4 were maintained in a stratified analysis.

Conclusions: Transfusions are common, heavily utilized, high-value palliative interventions that closely align with hospice's mission by improving symptoms. Our data suggests that patients receiving transfusions are less likely to enroll in hospice and enroll for shorter periods. One possible explanation is that patients delay hospice enrollment to continue receiving palliative benefit from transfusions. This aligns with surveys reporting most hospice providers do not offer transfusions, and transfusion-dependent patients spend markedly less time in hospice than their non-transfusion-dependent counterparts (median 6 days vs. 11 days, respectively; p<0.001) (Rodenbach et al, ASH Education 2024). Independent reimbursement of transfusion support for patients would remove barriers to hospice enrollment and improve their end-of-life care.

Chiara Lucia Perni, N/A: No relevant conflicts of interest to declare.